Pep2Tango Therapeutics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Pep2Tango Therapeutics Inc. - overview
Established
2021
Location
Potomac, MD, US
Primary Industry
Biotechnology
About
Based in Maryland, US, and founded in 2021 and led by Chief Executive Officer Cristina Rondinone, Pep2Tango Therapeutics Inc. operates as a biotech research company focused on developing treatments for obesity and related metabolic disorders. In November 2024, Pep2Tango Therapeutics Inc. raised an undisclosed amount of venture funding from Versant Ventures.
Pep2Tango Therapeutics developed new peptide drugs that target unmet medical needs, including metabolic, endocrine, CNS, and cardiovascular disorders. Its drug development approach for obesity focuses on unimolecular peptides that target multiple receptors, allowing for weight loss efficacy, muscle mass preservation, improved tolerability, and streamlined development and manufacturability. As of 2024, the firm’s approach focuses on creating unimolecular tetra-receptor agonist peptides that target four key receptors: GLP-1, GIP, amylin, and calcitonin.
Current Investors
Versant Ventures
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
www.pep2tango.com
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.